Robert Kramer - 09 Jun 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: President and CEO, Director
Issuer ticker: EBS
Reported as of: 09 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2023, 21:20:24 UTC
Prior SEC filing: 06 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Lynne Fox, Attorney-in-fact

Key filing fact

Robert Kramer filed Form 4 for Emergent BioSolutions Inc. (EBS) on 13 Jun 2023.

Key facts

This page summarizes Robert Kramer's Form 4 filing for Emergent BioSolutions Inc. (EBS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2023, 21:20.

Change

Previous filing in this sequence was filed on 06 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value: $0
Shares: +70,769
Change %: +24%
Price: $0.000000
Shares after: 364,520
Date: 09 Jun 2023
Ownership: Direct
Footnotes: F1

EBS transaction

Common Stock

Award

Transaction value: $0
Shares: +141,539
Change %: +39%
Price: $0.000000
Shares after: 506,059
Date: 09 Jun 2023
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EBS transaction Derivative

Employee Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +141,539
Change %: +36%
Price: $0.000000
Shares after: 535,051
Date: 09 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 141,539
Exercise price: $8.39
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Footnote F2

Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

Footnote F3

Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Footnote F4

Represents the corrected number of securities owned due to a computational error in prior Form-4s